




Searching News Database: CSL
HSMN NewsFeed - 28 Jul 2021
Medtronic Announces FDA Clearance and Results of Artificial Intelligence Algorithms for Cardiac Monitoring
Medtronic Announces FDA Clearance and Results of Artificial Intelligence Algorithms for Cardiac Monitoring
HSMN NewsFeed - 3 Jul 2020
IDELVION(R) Becomes First and Only Factor IX Therapy with 21-Day Prophylactic Dosing
IDELVION(R) Becomes First and Only Factor IX Therapy with 21-Day Prophylactic Dosing
HSMN NewsFeed - 23 Aug 2018
IDELVION(R) 3500 IU Vials Now Available to Provide Convenience to Patients
IDELVION(R) 3500 IU Vials Now Available to Provide Convenience to Patients
HSMN NewsFeed - 28 Aug 2017
CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform
CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform
HSMN NewsFeed - 21 Jul 2017
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA(R) (C1 Esterase Inhibitor Subcutaneous [Human])
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA(R) (C1 Esterase Inhibitor Subcutaneous [Human])
HSMN NewsFeed - 19 Aug 2014
FDA Approves Use of AFLURIA(R) Influenza Vaccine with PharmaJet’s Needle-Free Injector
FDA Approves Use of AFLURIA(R) Influenza Vaccine with PharmaJet’s Needle-Free Injector
HSMN NewsFeed - 3 Dec 2013
BioDelivery Sciences Announces Hiring of David Acheson as Vice President of Sales and Managed Markets
BioDelivery Sciences Announces Hiring of David Acheson as Vice President of Sales and Managed Markets
HSMN NewsFeed - 3 Sep 2013
CSL Behring Announces FDA Approval of a 10 g (50 mL) Vial Size for Hizentra(R)
CSL Behring Announces FDA Approval of a 10 g (50 mL) Vial Size for Hizentra(R)
HSMN NewsFeed - 28 Feb 2013
CSL Behring Receives FDA Approval to Expand the Indication for Corifact(R)
CSL Behring Receives FDA Approval to Expand the Indication for Corifact(R)
HSMN NewsFeed - 2 Aug 2012
Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
HSMN NewsFeed - 4 Apr 2011
PERCIVIA LLC Appoints Amit D. Munshi, President and Chief Executive Officer
PERCIVIA LLC Appoints Amit D. Munshi, President and Chief Executive Officer
HSMN NewsFeed - 27 Jan 2011
CSL Behring Receives National Marketing Authorization of Berinert(R) in Israel
CSL Behring Receives National Marketing Authorization of Berinert(R) in Israel
HSMN NewsFeed - 7 Dec 2009
Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board
Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board
HSMN NewsFeed - 26 Nov 2007
CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
HSMN NewsFeed - 4 Nov 2007
New Data Presented on GARDASIL(R), Merck's Cervical Cancer Vaccine, in Women Through Age 45
New Data Presented on GARDASIL(R), Merck's Cervical Cancer Vaccine, in Women Through Age 45
HSMN NewsFeed - 20 Jun 2007
Merck Provides Update on Status of Supplemental Biologics License Applications (sBLA) for GARDASIL(R)
Merck Provides Update on Status of Supplemental Biologics License Applications (sBLA) for GARDASIL(R)
HSMN NewsFeed - 9 May 2007
New England Journal of Medicine Publishes New Data on GARDASIL(R), Merck's Cervical Cancer Vaccine
New England Journal of Medicine Publishes New Data on GARDASIL(R), Merck's Cervical Cancer Vaccine
HSMN NewsFeed - 2 Apr 2007
FDA Approves Rhophylac(R) for the Treatment of Immune Thrombocytopenic Purpura (ITP)
FDA Approves Rhophylac(R) for the Treatment of Immune Thrombocytopenic Purpura (ITP)
HSMN NewsFeed - 22 Mar 2007
CDC Finalizes Advisory Panel Recommendations for GARDASIL(R), Merck's Cervical Cancer Vaccine
CDC Finalizes Advisory Panel Recommendations for GARDASIL(R), Merck's Cervical Cancer Vaccine
HSMN NewsFeed - 1 Feb 2007
CSL Behring and Bayer Extend Agreement for Supply of Helixate(R) Recombinant Coagulation Factor
CSL Behring and Bayer Extend Agreement for Supply of Helixate(R) Recombinant Coagulation Factor
HSMN NewsFeed - 18 Dec 2006
ZLB Behring Completes Purchase of CytoGam(R) Immunoglobulin Therapy From MedImmune
ZLB Behring Completes Purchase of CytoGam(R) Immunoglobulin Therapy From MedImmune
HSMN NewsFeed - 13 Nov 2006
Merck Launches National Advertising Campaign for GARDASIL(R), Merck's New Cervical Cancer Vaccine
Merck Launches National Advertising Campaign for GARDASIL(R), Merck's New Cervical Cancer Vaccine
HSMN NewsFeed - 1 Nov 2006
Merck's Cervical Cancer Vaccine, GARDASIL(R), Added to the CDC Vaccines for Children Contract
Merck's Cervical Cancer Vaccine, GARDASIL(R), Added to the CDC Vaccines for Children Contract
HSMN NewsFeed - 22 Sep 2006
European Commission Approves GARDASIL(R), Merck's Cervical Cancer Vaccine
European Commission Approves GARDASIL(R), Merck's Cervical Cancer Vaccine
HSMN NewsFeed - 28 Jul 2006
GARDASIL(R), Merck's Cervical Cancer Vaccine, Receives Positive Opinion from the European Medicines Agency
GARDASIL(R), Merck's Cervical Cancer Vaccine, Receives Positive Opinion from the European Medicines Agency
HSMN NewsFeed - 8 Jun 2006
FDA Approves Merck's GARDASIL(R), the World's First and Only Cervical Cancer Vaccine
FDA Approves Merck's GARDASIL(R), the World's First and Only Cervical Cancer Vaccine
Additional items found! 17

Members Archive contains
17 additional stories matching:
CSL
(Password required)
CSL
(Password required)